CEBP Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Vivo, I.
Right arrow Articles by Hunter, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Vivo, I.
Right arrow Articles by Hunter, D. J.
Cancer Epidemiology Biomarkers & Prevention Vol. 11, 489-492, May 2002
© 2002 American Association for Cancer Research

Short Communications

Association of CYP1B1 Polymorphisms and Breast Cancer Risk1

Immaculata De Vivo2, Susan E. Hankinson, Lisa Li, Graham A. Colditz and David J. Hunter

Departments of Epidemiology [I. D., S. E. H., G. A. C., D. J. H.] and Nutrition [D. J. H.], and the Harvard Center for Cancer Prevention [I. D., G. A. C., D. J. H.], Harvard School of Public Health, and the Channing Laboratory [I. D., S. E. H., L. L., G. A. C., D. J. H.], Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts 02115


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Cytochrome P450 1B1 catalyzes the conversion of 17-ß-estradiol (E2) to thecatechol estrogen metabolites 2-OH-E2 and 4-OH-E2 that have been postulated to be involved in mammary carcinogenesis. We sought to determine whether two common functional polymorphisms in Cytochrome P450 1B1, V432L (m1), and A453S (m2) are related to breast cancer risk. Using a nested case control design within the Nurses’ Health Study cohort, we genotyped 453 cases and 456 controls and found no significant association between m1[val/leu and leu/leu versus val/val, OR = 1 (CI, 0.72–1.45)] or m2 [asn/ser and ser/ser versus asn/asn, OR = 0.8 (CI, 0.62–1.15)] and breast cancer risk. However, we did observe women with the Val/Val (m1) genotype to have a higher percentage of estrogen receptor-positive tumors (P = 0.03). We did not observe any correlation with the m2 genotypes and estrogen receptor status. The association of the m1 and m2 genotypes on plasma hormone levels in postmenopausal control women not using hormone replacement therapy was also evaluated. Carriers of the m1 leu and m2 ser alleles had modestly higher estradiol levels but similar estrone and estrone sulfate levels. The results presented do not support a strong association between m1 and m2 and the risk of breast cancer.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
E23 is thought to have a role in mammary carcinogenesis. E2 is metabolized by either formation of the catechol estrogen derivatives 2-OH-E2 and 4-OH-E2 or by C-16-{alpha} hydroxylation. The CYP1B1 enzyme predominately catalyzes the formation of 4-OH-E2 (1, 2, 3) , the most carcinogenic estrogen in animal models (4) . Unlike the 2-OH-E2 derivative, 4-OH-E2 induces uterine adenocarcinoma (5) and can induce DNA single-strand breaks (6) . In one study, human breast cancer tissue had a significantly higher ratio of 4-OH-E2/2-OH-E2 compared with adjacent normal tissue (7) . In human breast cancer cell lines, the formation of 4-OH-E2 is inducible by dioxin, a common environmental contaminant (8) . Although CYP1B1 is expressed in a wide variety of tissues, expression is particularly high in the breast, prostate, and uterus (9 , 10) , supporting a role for CYP1B1 in hormone-mediated cancer. These findings underscore the importance of the CYP1B1 with regard to metabolism of environmental carcinogens and estrogens and its potential role in the initiation of tumors in estrogen-responsive organs, like the breast.

Two polymorphisms have been examined in relation to breast cancer risk, the m1 allele (Val to Leu at codon 432) and the m2 allele (Asn to Ser at codon 453). Recently, biochemical studies determined that the Val allele and the Asn allele had higher catalytic efficiency for the 4-hydroxylation of estradiol compared with their wild-type counterparts (11 , 12) . Changes in 4-hydroxylation of 17ß-estradiol are of particular interest because of the potential carcinogenicity and estrogenic activity of the 4-OH-E2.

In a case control study, Bailey et al. (13) , found no association with the m1 and m2 alleles and breast cancer risk. They did, however, find an association between the m1 Val/Val genotype and Caucasian breast cancer patients who had ER-positive breast cancer (P = 0.02); no correlation with the m2 allele was noted (13) . In a second case control study of 186 Asian breast cancer cases and 200 Asian controls, the authors found that women with the m1 Leu/Leu genotype had a 2-fold elevated risk of breast cancer compared with women with the Val/Val genotype (14) . This lack of consistency may be attributable to ethnic differences among studies. These authors were unable to evaluate receptor status.

In this study, we evaluated, among primarily Caucasian women, the relationship between the CYP1B1 alleles and breast cancer risk in a nested case control study within the NHS cohort. Given the role of CYP1B1 in estradiol metabolism, we also evaluated the relationship between the m1 and m2 alleles and circulating estrogen levels.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Study Population.
The NHS was initiated in 1976, when 121,700 United States registered nurses between the ages of 30 and 55 returned an initial questionnaire reporting medical histories and baseline health-related exposures. Between 1989 and 1990, blood samples were collected from 32,826 women. Incident breast cancers are identified by self-report and confirmed by medical record review. Eligible cases in this study consisted of women diagnosed with pathologically confirmed incident breast cancer after giving a blood specimen up to June 1, 1994. Controls were matched to cases on year of birth, menopausal status, and postmenopausal hormone use, as well as time of day, month, and fasting status at blood draw; menopause was defined as described previously (15) . The nested case control study consists of 453 incident breast cancer cases and 456 matched controls. The study sample for the plasma hormone analysis was restricted to postmenopausal controls not using hormone replacement therapy within 3 months of blood draw. The protocol was approved by the Committee on Human Subjects, Brigham and Women’s Hospital. Detailed information on exposure data and hormone assays have been described previously (15 , 16) .

Molecular Analysis.
All analyses were conducted with laboratory personnel blinded to case status. DNA was extracted from buffy coat fractions using the Qiagen QIAamp Blood Kit (Qiagen, Inc., Chadsworth CA). Genotyping was performed by automated DNA sequencing on the ABI 377X using BigDye-terminator Cycle Sequencing Ready Reaction Kit (PE Biosystems, Foster City, CA). Because of the close proximity of m1 to m2 within 60 bp, we were able to amplify both polymorphisms within one amplicon. PCR amplification of m1 and m2 was generated using primers 5'-CCAACACCTCTGTCTTGGGA-3' and 5'-GCTCATTTGGGTTGGCCCTG-3'. Heterozygotes were called at positions where the secondary peak height was >=45–50% of the primary peak height in both forward and reverse sequence reads for a subset of the samples. After establishing the criteria for base calling, the forward PCR primer was used for all subsequent sequencing reactions. All of the genotyping was performed by laboratory personnel unaware of case control status. For quality control, a random 10% of the samples were inserted to validate genotyping identification procedures; concordance for blinded samples was 100%.

Statistical Methods.
ORs and 95% CIs were calculated using conditional and unconditional logistic regression. In addition to the matching variables, we adjusted for the following breast cancer risk factors: BMI (kg/m2) at age 18 (continuous), weight gain since age 18 (<5 kg, 5-<20, and >=20), age of menarche (<12 years, 12, 13, and >=13), parity/age at first birth (nulliparous, one to two children/age at first birth <= 24 years, one to two children/age at first birth >= 24, three children/age at first birth <= 24 years, and three or more children/age at first birth >= 24 years), first-degree family history of breast cancer (yes/no), history of benign breast disease (yes/no), and duration of postmenopausal hormone use (never; past, <5 years and >=5; and current, <5 years and >=5). We also adjusted for age at menopause (continuous in years) in analyses limited to postmenopausal women. Indicator variables for CYP1B1 m1 and m2 were created using the Val/Val and Asn/Asn as the reference category in the regression models. These reference categories were used to be consistent with studies published previously (13 , 17) . Genotype was also evaluated using dichotomous variables, Val/Leu + Leu/Leu combined and Asn/Ser + Ser/Ser combined, as a gene dosage effect on breast cancer risk was not apparent. Unconditional multivariate models controlling for the matching factors enabled all controls to be included in analyses, limiting the cases to specified histopathological characteristics. Interactions between genotypes and breast cancer risk factors were evaluated by including interaction terms in multivariate logistic regression models. The likelihood ratio test was used to assess the statistical significance of these interactions.

Mixed regression models were used to evaluate the association between genotype and circulating hormone levels among postmenopausal controls not currently using postmenopausal hormones, controlling for BMI at blood draw and the matching variables. Hormone fractions were measured in three different batches; laboratory batch was treated as a random effect in all hormone analyses. We calculated least square mean plasma steroid hormone levels to evaluate differences in hormone levels between the genotypes. The natural logarithm of the plasma hormone values was used in the analyses to reduce the skewness of the regression residuals. We used the SAS statistical package for all analyses (Ref. 18 ; SAS Institute, Inc.).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Our study included 453 incident breast cancer cases and 456 cancer controls. A total of 348 cases and 345 controls were postmenopausal, and 64 cases and 69 controls were premenopausal, whereas menopausal status was uncertain for 41 cases and 42 controls. Self-reported major ethnicity/ancestry was similar between cases and controls (cases versus controls; Southern European: 18.1 versus 16.4%, Scandinavian: 8.5 versus 8.5%, and other Caucasian: 62 versus 62%). Asians, Hispanics, and African-Americans comprised <1% of cases or controls.

The prevalence of the m1 Val allele was similar to previous reports in Caucasian women (45% NHS cases and 42% NHS controls compared with 40%; Ref. 13 ). The prevalence of the m2 Ser allele was also similar to reports published previously in Caucasian women (16% NHS cases and 18% NHS controls compared with 17.4%; Ref. 13 ). The calculated frequencies for the m1 alleles (Val and Leu) were 0.46 and 0.54, respectively, in the cases and 0.42 and 0.58 in the controls. For the m2 alleles (Asn and Ser), the frequencies were 0.84 and 0.16 in the cases and 0.81 and 0.19 in the controls, respectively. Genotype frequencies for the m1 alleles were in Hardy-Weinberg equilibrium for cases ({chi}2 = 0.43, Df = 1, and P = 0.51) but slightly out of Hardy-Weinberg equilibrium for the controls ({chi}2 = 4.1, Df = 1, and P = 0.04). This finding is most likely attributable to chance as no genotyping errors were detected among the blinded quality control samples, and data for the cases were in equilibrium. For the m2 alleles, the genotype frequencies for the cases ({chi}2 = 0.58, Df = 1, and P = 0.45) and the controls ({chi}2 = 0.09, Df = 1, and P = 0.76) were in Hardy-Weinberg equilibrium. The m1 and m2 polymorphisms are not in linkage disequilibrium. We found no significant associations between any genotype frequencies and risk of breast cancer (Table 1)Citation . The results remained unchanged after stratifying by menopausal status, hormone use, and age at menarche for all genotypes. We did not find any significant associations between any of the genotypes and specific strata of breast cancer defined by receptor status (Table 2)Citation . However, we did observe an association with receptor status and genotype. Women who had ER-positive tumors were more likely to have the Val/Val genotype ({chi}2 = 4.87, P = 0.03) compared with women with ER-negative tumors (24 versus 10%). These findings are consistent with those reported by Bailey et al. (13) . Additionally consistent with Bailey et al. is the lack of an association with ER status for the m2 genotypes.


View this table:
[in this window]
[in a new window]
  		Table 1 Association between CYP1B1 genotype and breast cancer risk

 

View this table:
[in this window]
[in a new window]
  		Table 2 Association between CYP1B1 genotype and breast cancer risk by histological subtype and receptor status

 
When evaluating the relationship of genotype with plasma hormone levels among controls, we calculated the least squared geometric mean plasma steroid hormone levels for each genotype (Table 3)Citation . Compared with women with the Val/Val genotype, women with the Val/Leu and Leu/Leu genotype did not have elevated levels of estrone-sulfate or estrone; however, there was an increased level of estradiol (8.37%, P = 0.05). Similarly, compared with women with the Asn/Asn genotype, women with the Asn/Ser and Ser/Ser genotype did not have elevated levels of estrone-sulfate or estrone; however, there was an increased level of estradiol (16.5%, P = 0.03). We further evaluated the combination of m1 and m2 on breast cancer risk and observed no association.


View this table:
[in this window]
[in a new window]
  		Table 3 Least square geometric mean hormone levelsa among postmenopausal controls by CYP1B1 genotypes

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
CYP1B1 has an important role in estrogen metabolism. It catalyzes the formation of 4-hydroxyestradiol, a carcinogenic metabolite that retains significant estrogenic activity (2) . Several polymorphisms have been identified in CYP1B1, two of which have been studied in relation to breast cancer. The Val432Leu (m1) and the Asn453Ser (m2) polymorphisms both result in an amino acid change in exon 3, which encodes the heme-binding domain, the region critical to the catalytic function of CYP1B1 (13) . Recent functional studies show differences between wild-type CYP1B1 and variants in estrogen hydroxylation; specifically, the ratio of 4-OH-E2:2-OH-E2 was higher for both the Val allele and the Asn allele (11 , 12) . Higher levels of 4-OH-E2 have been reported in breast cancer tissue (7) . When treating MCF-7 breast cancer cells with 4-OH-E2, the rate of cell proliferation and the expression of estrogen-inducible genes were increased, compared with treatment with 2-OH-E2 (19 , 20) . In our study, the high activity alleles are not associated with increased breast cancer risk, which is consistent with one other case control study that included 164 Caucasian cases and controls and 59 African-American cases and controls (13) . Additionally consistent with the previous study, and with the recent biochemical data suggesting an increase in the enzymatic activity of the Val allele, is the association between the m1 Val polymorphism and ER-positive status. We found a marginally significant decrease in estradiol levels in women with the Val allele. Assays under development for estrogen metabolites, produced by CYP1B1, could be more informative, as these markers may serve as a more direct measure of CYP1B1 enzymatic activity.

Our results suggest that despite a potential association with estradiol levels, neither the V432L nor the A453S polymorphisms in the CYP1B1 gene alone or in combination are sufficient to substantially influence breast cancer risk in Caucasian women.


   Acknowledgments
 
We thank the participants of the NHS for their continuing exceptional cooperation, Pamela Lescault for technical assistance, and Frank Speizer, principal investigator of the NHS, for his support.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by NIH Grants CA65725, CA87969, and CA49449 I.D. is partially supported by a grant from the American Cancer Society (RPG-00-061-01-CCE). Back

2 To whom requests for reprints should be addressed, at Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115. E-mail: Devivo{at}channing.harvard.edu Back

3 The abbreviations used are: E2, 17-ß-estradiol; ER, estrogen receptor; CYP1B1, cytochrome P450 1B1; NHS, Nurses’ Health Study; OR, odds ratio; CI, confidence interval; BMI, body mass index. Back

Received 10/12/01; revised 2/15/02; accepted 2/24/02.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Spink D., Eugster H-P., Lincoln D., II, Schuetz E., Johnson J., Kaminsky L., Gierthy J. 17ß-Estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch. Biochem. Biophys., 293: 342-348, 1992.[Medline]
  2. Hayes C., Spink D., Spink B., Cao J., Walker N., Sutter T. 17 ß-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl. Acad. Sci. USA, 93: 9776-9781, 1996.[Abstract/Free Full Text]
  3. Spink D., Spink B., Cao J., Gierthy J., Hayes C., Li Y., Sutter T. Induction of cytochrome P450 1B1 and catechol estrogen metabolism in ACHN human renal adenocarcinoma cells. J. Steroid Biochem. Mol. Biol., 62: 223-232, 1997.[Medline]
  4. Li J., Li S. Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed. Proc., 46: 1858-1863, 1987.[Medline]
  5. Newbold R., Liehr J. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res, 60: 235-237, 2000.[Abstract/Free Full Text]
  6. Han X., Liehr J. DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: hormone-induced free radical damage preceding renal malignancy. Carcinogenesis (Lond.), 15: 997-1000, 1994.[Abstract/Free Full Text]
  7. Liehr J., Ricci M. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc. Natl. Acad. Sci. USA, 93: 3294-3296, 1996.[Abstract/Free Full Text]
  8. Spink D., Hayes C., Young N., Christou M., Sutter T., Jefcoate C., Gierthy J. The effects of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17 ß-estradiol 4-hydroxylase. J. Steroid Biochem. Mol. Biol., 51: 251-258, 1994.[Medline]
  9. McKay J., Melvin W., Ah-See A., Ewen S., Greenlee W., Marcus C., Burke M., Murray G. Expression of cytochrome P450 CYP1B1 in breast cancer. FEBS Lett., 374: 270-272, 1995.[Medline]
  10. Murray G., Taylor M., McFadyen M., McKay J., Greenlee W., Burke M., Melvin W. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res, 57: 3026-3031, 1997.[Abstract/Free Full Text]
  11. Shimada T., Watanabe J., Kawajiri K., Sutter T., Guengerich F., Gillam E., Inoue K. Catalytic properties of human polymorphic cytochrome P450 1B1 variants. Carcinogenesis (Lond.), 20: 1607-1613, 1999.[Abstract/Free Full Text]
  12. Hanna I., Dawling S., Roodi N., Guengerich F., Parl F. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res., 60: 3440-3444, 2000.[Abstract/Free Full Text]
  13. Bailey L., Roodi N., Dupont W., Parl F. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res., 58: 5038-5041, 1998.[Abstract/Free Full Text]
  14. Zheng W., Xie D-W., Jin F., Cheng J., Dai Q., Wen W-Q., Shu X-O., Gao Y-T. Genetic polymorphism of P450 1B1 and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev., 9: 147-150, 2000.[Abstract/Free Full Text]
  15. Haiman C., Hankinson S., Spiegelman D., Colditz G., Willett W., Speizer F., Kelsey K., Hunter D. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res., 59: 1015-1020, 1999.[Abstract/Free Full Text]
  16. Hankinson S., Willett W., Manson J., Colditz G., Hunter D., Spiegelman D., Barbieri R., Speizer F. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. (Bethesda), 90: 1292-1299, 1998.[Abstract/Free Full Text]
  17. Goodman M., McDuffie K., Kolonel L., Terada K., Donlon T., Wilkens L., Guo C., Le Marchand L. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol. Biomarkers Prev., 10: 209-216, 2001.[Abstract/Free Full Text]
  18. SAS Institute . I. Changes and Enhancements. SAS Technical Report, Release 6.07, 1992.
  19. Schultze N., Vollmer G., Tiemann I., Geiger M., Knuppen R. Catecholestrogens are MCF-7 cell estrogen receptor agonists. J. Steroid Biochem. Mol. Biol., 46: 781-789, 1993.[Medline]
  20. Schultze N., Vollmer G., Knuppen R. Catecholestrogens are agonists of estrogen receptor dependent gene expression in MCF-7 cells. J. Steroid Biochem. Mol. Biol., 48: 453-461, 1994.[Medline]



This article has been cited by other articles:


Home page
 Am J EpidemiolHome page
V. Paracchini, S. Raimondi, I. T. Gram, D. Kang, N. A. Kocabas, V. N. Kristensen, D. Li, F. F. Parl, T. Rylander-Rudqvist, P. Soucek, et al.
Meta- and Pooled Analyses of the Cytochrome P-450 1B1 Val432Leu Polymorphism and Breast Cancer: A HuGE-GSEC Review
Am. J. Epidemiol., January 15, 2007; 165(2): 115 - 125.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
A. J. De Roos, N. Rothman, M. Brown, D. A. Bell, G. S. Pittman, W. R. Shapiro, R. G. Selker, H. A. Fine, P. M. Black, and P. D. Inskip
Variation in genes relevant to aromatic hydrocarbon metabolism and the risk of adult brain tumors.
Neuro-oncol, April 1, 2006; 8(2): 145 - 155.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. E. Cribb, M. J. Knight, D. Dryer, J. Guernsey, K. Hender, M. Tesch, and T. M. Saleh
Role of polymorphic human cytochrome p450 enzymes in estrone oxidation.
Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 551 - 558.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
T. M. Sissung, D. K. Price, A. Sparreboom, and W. D. Figg
Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention
Mol. Cancer Res., March 1, 2006; 4(3): 135 - 150.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
K. Visvanathan, L. Gallicchio, C. Schilling, J. K. Babus, L. M. Lewis, S. R. Miller, H. Zacur, and J. A. Flaws
Cytochrome Gene Polymorphisms, Serum Estrogens, and Hot Flushes in Midlife Women
Obstet. Gynecol., December 1, 2005; 106(6): 1372 - 1381.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. S. Cicek, X. Liu, G. Casey, and J. S. Witte
Role of Androgen Metabolism Genes CYP1B1, PSA/KLK3, and CYP11{alpha} in Prostate Cancer Risk and Aggressiveness
Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2173 - 2177.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. Le Marchand, T. Donlon, L. N. Kolonel, B. E. Henderson, and L. R. Wilkens
Estrogen Metabolism-Related Genes and Breast Cancer Risk: The Multiethnic Cohort Study
Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1998 - 2003.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
L.A. Hefler, C. Grimm, G. Heinze, C. Schneeberger, M.W. Mueller, A. Muendlein, J.C. Huber, S. Leodolter, and C.B. Tempfer
Estrogen-metabolizing gene polymorphisms and age at natural menopause in Caucasian women
Hum. Reprod., May 1, 2005; 20(5): 1422 - 1427.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
W. Wen, Q. Cai, X.-O. Shu, J.-R. Cheng, F. Parl, L. Pierce, Y.-T. Gao, and W. Zheng
Cytochrome P450 1B1 and Catechol-O-Methyltransferase Genetic Polymorphisms and Breast Cancer Risk in Chinese Women: Results from the Shanghai Breast Cancer Study and a Meta-analysis
Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 329 - 335.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Bandiera, S. Weidlich, V. Harth, P. Broede, Y. Ko, and T. Friedberg
Proteasomal Degradation of Human CYP1B1: Effect of the Asn453Ser Polymorphism on the Post-Translational Regulation of CYP1B1 Expression
Mol. Pharmacol., February 1, 2005; 67(2): 435 - 443.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. Rylander-Rudqvist, S. Wedren, G. Jonasdottir, S. Ahlberg, E. Weiderpass, I. Persson, and M. Ingelman-Sundberg
Cytochrome P450 1B1 Gene Polymorphisms and Postmenopausal Endometrial Cancer Risk
Cancer Epidemiol. Biomarkers Prev., September 1, 2004; 13(9): 1515 - 1520.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. McGrath, S. E. Hankinson, L. Arbeitman, G. A. Colditz, D. J. Hunter, and I. De Vivo
Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility
Carcinogenesis, April 1, 2004; 25(4): 559 - 565.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Zhu, M. R. Spitz, C. I. Amos, J. Lin, M. B. Schabath, and X. Wu
An Evolutionary Perspective on Single-Nucleotide Polymorphism Screening in Molecular Cancer Epidemiology
Cancer Res., March 15, 2004; 64(6): 2251 - 2257.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. S. Tworoger, J. Chubak, E. J. Aiello, C. M. Ulrich, C. Atkinson, J. D. Potter, Y. Yasui, P. L. Stapleton, J. W. Lampe, F. M. Farin, et al.
Association of CYP17, CYP19, CYP1B1, and COMT Polymorphisms with Serum and Urinary Sex Hormone Concentrations in Postmenopausal Women
Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 94 - 101.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
T. Rylander-Rudqvist, S. Wedren, F. Granath, K. Humphreys, S. Ahlberg, E. Weiderpass, M. Oscarson, M. Ingelman-Sundberg, and I. Persson
Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk
Carcinogenesis, September 1, 2003; 24(9): 1533 - 1539.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Gibson, J. H. Gill, P. A. Khan, J. M. Seargent, S. W. Martin, P. A. Batman, J. Griffith, C. Bradley, J. A. Double, M. C. Bibby, et al.
Cytochrome P450 1B1 (CYP1B1) Is Overexpressed in Human Colon Adenocarcinomas Relative to Normal Colon: Implications for Drug Development
Mol. Cancer Ther., June 1, 2003; 2(6): 527 - 534.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Vivo, I.
Right arrow Articles by Hunter, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Vivo, I.
Right arrow Articles by Hunter, D. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation